SMARCB1 and neoplasm: Within the SMARCB1-deficient neoplasm cohort, EpS showed the highest EA and EAA compared to MRT and ATRT (p < 0.01) across all three DNAm clocks (Fig. 1A–C and supplementary 3, Table 2 for all EA and EAA values inferred in the cohort).